The story

Mazdutide began at Eli Lilly as LY3305677, an oxyntomodulin analogue. In 2020 Innovent Biologics in Suzhou licensed it for China and led its development as IBI362, with Linong Ji of Peking University People's Hospital at the head of the work. Chinese groups published its effect first in 2021 and 2022, then in 2025 at 4 mg and 6 mg, and China's drug authority approved it on 27 June 2025 under the name Xinermei, the first medicine of its kind. A US programme followed in 2026. Russian endocrinologists, measuring oxyntomodulin in people losing weight after bariatric surgery, describe the same dual signal as one of the body's own weight-loss hormones.